Luis Garza, M.D., Ph.D., on What Hidradenitis Suppurativa Is Not
Luis Garza, M.D., Ph.D., defines hidradenitis suppurativa by its misconceptions in a new interview — a corrective aimed at the diagnostic delays HS patients face.
Topic
Biologic Therapy
Topic
Biologic Therapy
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2, Level Up Data
Dermatology Times spotlights three atopic dermatitis storylines from EADV 2026 in Europe: the biologic tilrekimig, RAC2 pathway i…
Daxdilimab Improved Discoid Lupus Skin Activity by Week 4
Daxdilimab improved discoid lupus skin activity by week 4, HCPLive reports — an early efficacy signal for interferon-pathway bloc…
Psoriasis Disparities: Where Dermatology Still Fails Patients
Physicians Weekly lays out clinic-level strategies for closing psoriasis care gaps — from skin-of-color diagnosis to biologic acc…
Litifilimab Eyes More Than Skin Clearance in Cutaneous Lupus
Litifilimab is drawing attention in cutaneous lupus care for what it may deliver beyond visible skin clearance — here's what derm…
Dual Cytokine Blocker Holds Psoriasis at Two-Year Mark
Bioengineer.org this week reported a dual cytokine blocker held psoriasis in remission for two full years. The molecule hits two…
Escalating HS Therapy After Biologic Failure: Dermatology Times Case 2
Dermatology Times' Case 2 examines escalation strategy after biologic failure in hidradenitis suppurativa, where approved options…
J&J Psoriasis Drug Holds Clearance Through Two Years
Johnson & Johnson's psoriasis therapy sustained skin clearance through two years of follow-up, according to a MyChesCo report. Th…
Personalizing Psoriasis Care: Inside the Comprehensive-Management Push
A Physician's Weekly review reframes psoriasis care around the whole patient, calling for comorbidity screening, patient-profile…
Atopic Dermatitis Mental Health Burden Goes 'Invisible,' Feature Argues
Everyday Health frames atopic dermatitis as an 'invisible' mental-health burden. The piece argues clinician-rated scores miss anx…